Page 2 - Best Nasopharyngeal cancer doctors in Turkey: TOP 31 doctors

Assoc. Prof. Nail Paksoy specializes in nasopharyngeal cancer at Medipol Bahçelievler Hospital, bringing extensive oncology expertise.

• Board-certified in medical oncology by ESMO
• Fellowship-trained at Istanbul University Oncology Institute
• Participated in international clinical trials for advanced cancer treatments
• Published research on various oncology topics in peer-reviewed journals

Dr. Ozden brings over a decade of specialized medical oncology experience to nasopharyngeal cancer cases. He trained at Istanbul University's prestigious Cerrahpaşa Faculty of Medicine.

• Completed medical oncology subspecialty at Kocaeli University
• Practiced internal medicine and oncology since 2004
• English-language medical education background
• Works at VM Medical Park Pendik Hospital

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Trained in radiation oncology at Marmara University, specializing in precise cancer treatment techniques.

• Specialization in radiation oncology completed in 2016
• Medical degree from Marmara University Faculty of Medicine
• Practices at Emsey Hospital

Associate Professor Dr. Emrah Eraslan specializes in medical oncology with a focus on various cancers, including nasopharyngeal cancer, at Koru Ankara Hospital.

• Over 21 years of experience of experience in internal medicine and medical oncology
• Trained at Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital
• Published multiple papers contributing to oncology research
• Specializes in breast, prostate, lung, and colorectal cancers